Genmab’s Oncology Breakthroughs at ASCO 2025: A Catalyst-Driven Path to Growth

The upcoming American Society of Clinical Oncology (ASCO) 2025 conference is poised to be a defining moment for Genmab A/S (GMAB), as two of its late-stage oncology assets—rinatabart sesutecan (Rina-S®) and epcoritamab (EPKINLY®)—present pivotal data addressing high-unmet-need cancer indications. With Rina-S’s first-in-human results in endometrial cancer and epcoritamab’s 3-year follow-up data in diffuse large B-cell lymphoma (DLBCL), Genmab stands at the intersection of scientific innovation and commercial opportunity. These catalysts, coupled with its strategic partnership with AbbVie and recent regulatory wins, position the stock for significant upside as data readouts approach.

Rina-S®: Breaking Ground in Endometrial Cancer

Rina-S®, an antibody-drug conjugate (ADC) targeting FRα-expressing tumors, is set to deliver its first clinical data in recurrent/advanced endometrial cancer at ASCO. The Phase 1/2 trial (GCT1184-01) cohort B2 results (Abstract 3039) will provide critical efficacy and safety insights for a disease with soaring mortality rates and limited treatment options. Endometrial cancer’s 5-year survival rate drops to just 18% in metastatic cases, underscoring the urgent need for therapies like Rina-S®.

The FDA’s Fast Track designation in January 2024 for Rina-S® in platinum-resistant ovarian cancer—a related indication with shared FRα expression—hints at a regulatory tailwind. While the ASCO data focuses on endometrial cancer, success here could expand Rina-S®’s addressable market.

Epcoritamab: Proving Long-Term Value in DLBCL

Epcoritamab, a T-cell–engaging bispecific antibody, will present 3-year follow-up data from its Phase 1/2 EPCORE NHL-1 study (Abstract 7043). The focus on patients with relapsed/refractory DLBCL who achieved complete response (CR) at 2 years aims to solidify its position as a durable monotherapy option. DLBCL, the most common aggressive lymphoma, has seen limited progress in long-term survival, making epcoritamab’s potential a game-changer.

Epcoritamab’s global sales momentum is already evident: in Q1 2025, Genmab reported a 19% year-over-year revenue increase, driven partly by EPKINLY® sales. AbbVie’s collaboration has been instrumental, with profit-sharing arrangements accelerating commercialization. Notably, EPKINLY® secured an additional Japan approval in Q1 2025 for follicular lymphoma, expanding its market reach.

Strategic Partnership with AbbVie: Fueling Growth

Genmab’s partnership with AbbVie is a cornerstone of its success. Epcoritamab’s global development, including ongoing Phase 3 trials in combination therapies, leverages AbbVie’s oncology expertise and commercial infrastructure. The Japan approval highlights their joint focus on geographic expansion, while shared profit-sharing structures align incentives.

Financially, Genmab’s $589 million in Q1 2025 royalties (up 30% year-over-year) reflect the strength of its pipeline, with EPKINLY® contributing significantly. As AbbVie’s oncology portfolio grows (+7.5% operationally in Q1), investors can expect continued synergy benefits.

Investor Update: The Catalyst Crucible

Genmab’s June 2, 2025 virtual review of Rina-S® data marks a critical risk-reward inflection point. Positive endometrial cancer results could catalyze a revaluation of Rina-S®’s commercial potential, potentially accelerating FDA submissions. Meanwhile, epcoritamab’s long-term data could allay concerns about durability, further solidifying its position in DLBCL treatment paradigms.

Why Act Now?

• Near-Term Catalysts: ASCO data for Rina-S and epcoritamab are imminent, with results likely to shape valuation.
• Pipeline Validation: Success in these trials could unlock multi-billion-dollar markets.
• Partnership Strength: AbbVie’s resources and global reach mitigate commercial risks.
• Valuation: Genmab’s current valuation does not yet reflect Rina-S’s potential or epcoritamab’s long-term profile.

Conclusion: Positioning for Oncology’s Next Wave

Genmab is at a pivotal juncture, with ASCO 2025 serving as a catalyst to validate its pipeline and accelerate growth. Rina-S’s entry into endometrial cancer and epcoritamab’s long-term efficacy data represent transformative opportunities in underserved markets. With AbbVie’s partnership bolstering execution and the June 2 investor event looming, now is the time to position ahead of what could be a breakout quarter.

Investors should act decisively: Genmab’s stock is primed to surge as these data readouts redefine its oncology leadership. The path to approval—and commercialization—is clear. The question is: Will you be on the right side of it?